|
1
|
Feldman BJ and Feldman D: The development
of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yap TA, Zivi A, Omlin A and de Bono JS:
The changing therapeutic landscape of castration-resistant prostate
cancer. Nat Rev Clin Oncol. 8:597–610. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Eisenberger MA and Walsh PC: Early
androgen deprivation for prostate cancer? N Engl J Med.
341:1837–1838. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Visakorpi T, Hyytinen E, Koivisto P, et
al: In vivo amplification of the androgen receptor gene and
progression of human prostate cancer. Nat Genet. 9:401–406. 1995.
View Article : Google Scholar
|
|
5
|
Taplin ME, Bubley GJ, Shuster TD, et al:
Mutation of the androgen-receptor gene in metastatic
androgen-independent prostate cancer. N Engl J Med. 332:1393–1398.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Taplin ME, Bubley GJ, Ko YJ, et al:
Selection for androgen receptor mutations in prostate cancers
treated with androgen antagonist. Cancer Res. 59:2511–2515.
1999.PubMed/NCBI
|
|
7
|
Yamaoka M, Hara T and Kusaka M: Overcoming
persistent dependency on androgen signaling after progression to
castration-resistant prostate cancer. Clin Cancer Res.
16:4319–4324. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Araki S, Omori Y, Lyn D, et al:
Interleukin-8 is a molecular determinant of androgen independence
and progression in prostate cancer. Cancer Res. 67:6854–6862. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu Y, Josson S, Fang F, et al: RelB
enhances prostate cancer growth: implications for the role of the
nuclear factor-κB alternative pathway in tumorigenicity. Cancer
Res. 69:3267–3271. 2009.PubMed/NCBI
|
|
10
|
Tannock IF, de Wit R, Berry WR, et al:
Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Serpa Neto A, Tobias-Machado M, Kaliks R,
Wroclawski ML, Pompeo AC and Del Giglio A: Ten years of
docetaxel-based therapies in prostate adenocarcinoma: a systematic
review and meta-analysis of 2244 patients in 12 randomized clinical
trials. Clin Genitourin Cancer. 9:115–123. 2011.PubMed/NCBI
|
|
12
|
Marech I, Vacca A, Ranieri G, Gnoni A and
Dammacco F: Novel strategies in the treatment of
castration-resistant prostate cancer (Review). Int J Oncol.
40:1313–1320. 2012.PubMed/NCBI
|
|
13
|
Seruga B and Tannock IF:
Chemotherapy-based treatment for castration-resistant prostate
cancer. J Clin Oncol. 29:3686–3694. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
El-Amm J and Aragon-Ching JB: The changing
landscape in the treatment of metastatic castration-resistant
prostate cancer. Ther Adv Med Oncol. 5:25–40. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shelanski ML, Gaskin F and Cantor CR:
Microtubule assembly in the absence of added nucleotides. Proc Natl
Acad Sci USA. 70:765–768. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McGrogan BT, Gilmartin B, Carney DN and
McCann A: Taxanes, microtubules and chemoresistant breast cancer.
Biochim Biophys Acta. 1785:96–132. 2008.PubMed/NCBI
|
|
17
|
Zhu J, Beattie EC, Yang Y, Wang HJ, Seo JY
and Yang LX: Centrosome impairments and consequent cytokinesis
defects are possible mechanisms of taxane drugs. Anticancer Res.
25:1919–1925. 2005.PubMed/NCBI
|
|
18
|
Fabbri F, Amadori D, Carloni S, et al:
Mitotic catastrophe and apoptosis induced by docetaxel in
hormone-refractory prostate cancer cells. J Cell Physiol.
217:494–501. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kramer G, Schwarz S, Hägg M, Havelka AM
and Linder S: Docetaxel induces apoptosis in hormone refractory
prostate carcinomas during multiple treatment cycles. Br J Cancer.
94:1592–1598. 2006.
|
|
20
|
Mediavilla-Varela M, Pacheco FJ, Almaguel
F, et al: Docetaxel-induced prostate cancer cell death involves
concomitant activation of caspase and lysosomal pathways and is
attenuated by LEDGF/p75. Mol Cancer. 8:682009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim JY, Chung JY, Lee SG, et al: Nuclear
interaction of Smac/DIABLO with Survivin at G2/M arrest prompts
docetaxel-induced apoptosis in DU145 prostate cancer cells. Biochem
Biophys Res Commun. 350:949–954. 2006. View Article : Google Scholar
|
|
22
|
Kuroda K, Liu H, Kim S, Guo M, Navarro V
and Bander NH: Docetaxel down-regulates the expression of androgen
receptor and prostate-specific antigen but not prostate-specific
membrane antigen in prostate cancer cell lines: implications for
PSA surrogacy. Prostate. 69:1579–1585. 2009. View Article : Google Scholar
|
|
23
|
Seruga B, Ocana A and Tannock IF: Drug
resistance in metastatic castration-resistant prostate cancer. Nat
Rev Clin Oncol. 8:12–23. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sissung TM, Baum CE, Deeken J, et al:
ABCB1 genetic variation influences the toxicity and clinical
outcome of patients with androgen-independent prostate cancer
treated with docetaxel. Clin Cancer Res. 14:4543–4549. 2008.
View Article : Google Scholar
|
|
25
|
O’Neill AJ, Prencipe M, Dowling C, et al:
Characterisation and manipulation of docetaxel resistant prostate
cancer cell lines. Mol Cancer. 10:1262011.PubMed/NCBI
|
|
26
|
Xie Y, Xu K, Linn DE, et al: The 44-kDa
Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its
multimerization and drug-resistant activity in human prostate
cancer cells. J Biol Chem. 283:3349–3356. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Terry S, Ploussard G, Allory Y, et al:
Increased expression of class III β-tubulin in castration-resistant
human prostate cancer. Br J Cancer. 101:951–956. 2009.
|
|
28
|
Ploussard G, Terry S, Maille P, et al:
Class III β-tubulin expression predicts prostate tumor
aggressiveness and patient response to docetaxel-based
chemotherapy. Cancer Res. 70:9253–9264. 2010.
|
|
29
|
Hara T, Ushio K, Nishiwaki M, et al: A
mutation in β-tubulin and a sustained dependence on androgen
receptor signalling in a newly established docetaxel-resistant
prostate cancer cell line. Cell Biol Int. 34:177–184. 2010.
|
|
30
|
Heidenberg HB, Bauer JJ, McLeod DG, Moul
JW and Srivastava S: The role of the p53 tumor suppressor gene in
prostate cancer: a possible biomarker? Urology. 48:971–979. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gan L, Wang J, Xu H and Yang X: Resistance
to docetaxel-induced apoptosis in prostate cancer cells by
p38/p53/p21 signaling. Prostate. 71:1158–1166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yoshino T, Shiina H, Urakami S, et al:
Bcl-2 expression as a predictive marker of hormone-refractory
prostate cancer treated with taxane-based chemotherapy. Clin Cancer
Res. 12:6116–6124. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lebedeva I, Rando R, Ojwang J, Cossum P
and Stein CA: Bcl-xL in prostate cancer cells: effects of
overexpression and down-regulation on chemosensitivity. Cancer Res.
60:6052–6060. 2000.PubMed/NCBI
|
|
34
|
Tantivejkul K, Loberg RD, Mawocha SC, et
al: PAR1-mediated NF-κB activation promotes survival of prostate
cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem.
96:641–652. 2005.PubMed/NCBI
|
|
35
|
Patterson SG, Wei S, Chen X, et al: Novel
role of Stat1 in the development of docetaxel resistance in
prostate tumor cells. Oncogene. 25:6113–6122. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zemskova M, Sahakian E, Bashkirova S and
Lilly M: The PIM1 kinase is a critical component of a survival
pathway activated by docetaxel and promotes survival of
docetaxel-treated prostate cancer cells. J Biol Chem.
283:20635–20644. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shimada K, Nakamura M, Ishida E, Kishi M,
Yonehara S and Konishi N: Contributions of mitogen-activated
protein kinase and nuclear factor kappa B to
N-(4-hydroxyphenyl)retinamide-induced apoptosis in prostate
cancer cells. Mol Carcinog. 35:127–137. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Palayoor ST, Youmell MY, Calderwood SK,
Coleman CN and Price BD: Constitutive activation of IκB kinase α
and NF-κB in prostate cancer cells is inhibited by ibuprofen.
Oncogene. 18:7389–7394. 1999.
|
|
39
|
Domingo-Domenech J, Oliva C, Rovira A, et
al: Interleukin 6, a nuclear factor-κB target, predicts resistance
to docetaxel in hormone-independent prostate cancer and nuclear
factor-κB inhibition by PS-1145 enhances docetaxel antitumor
activity. Clin Cancer Res. 12:5578–5586. 2006.
|
|
40
|
Zerbini LF, Wang Y, Cho JY and Libermann
TA: Constitutive activation of nuclear factor κB p50/p65 and Fra-1
and JunD is essential for deregulated interleukin 6 expression in
prostate cancer. Cancer Res. 63:2206–2215. 2003.
|
|
41
|
Michalaki V, Syrigos K, Charles P and
Waxman J: Serum levels of IL-6 and TNF-α correlate with
clinicopathological features and patient survival in patients with
prostate cancer. Br J Cancer. 90:2312–2316. 2004.
|
|
42
|
Singh RK and Lokeshwar BL: Depletion of
intrinsic expression of Interleukin-8 in prostate cancer cells
causes cell cycle arrest, spontaneous apoptosis and increases the
efficacy of chemotherapeutic drugs. Mol Cancer. 8:572009.
View Article : Google Scholar
|
|
43
|
Inoue K, Slaton JW, Eve BY, et al:
Interleukin 8 expression regulates tumorigenicity and metastases in
androgen-independent prostate cancer. Clin Cancer Res. 6:2104–2119.
2000.PubMed/NCBI
|
|
44
|
Lu Y, Cai Z, Galson DL, et al: Monocyte
chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine
factor for prostate cancer growth and invasion. Prostate.
66:1311–1318. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shirotake S, Miyajima A, Kosaka T, et al:
Regulation of monocyte chemoattractant protein-1 through
angiotensin II type 1 receptor in prostate cancer. Am J Pathol.
180:1008–1016. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Qian DZ, Rademacher BL, Pittsenbarger J,
et al: CCL2 is induced by chemotherapy and protects prostate cancer
cells from docetaxel-induced cytotoxicity. Prostate. 70:433–442.
2010.
|
|
47
|
Roca H, Varsos ZS and Pienta KJ: CCL2 is a
negative regulator of AMP-activated protein kinase to sustain mTOR
complex-1 activation, survivin expression, and cell survival in
human prostate cancer PC3 cells. Neoplasia. 11:1309–1317. 2009.
|
|
48
|
Loberg RD, Day LL, Harwood J, et al: CCL2
is a potent regulator of prostate cancer cell migration and
proliferation. Neoplasia. 8:578–586. 2006. View Article : Google Scholar
|
|
49
|
Shiota M, Kashiwagi E, Yokomizo A, et al:
Interaction between docetaxel resistance and castration resistance
in prostate cancer: implications of Twist1, YB-1, and androgen
receptor. Prostate. 73:1336–1344. 2013. View Article : Google Scholar
|
|
50
|
Marin-Aguilera M, Codony-Servat J, Kalko
SG, et al: Identification of docetaxel resistance genes in
castration-resistant prostate cancer. Mol Cancer Ther. 11:329–339.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Patrikainen L, Porvari K, Kurkela R,
Hirvikoski P, Soini Y and Vihko P: Expression profiling of PC3 cell
line variants and comparison of MIC-1 transcript levels in benign
and malignant prostate. Eur J Clin Invest. 37:126–133. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Karan D, Kelly DL, Rizzino A, Lin MF and
Batra SK: Expression profile of differentially-regulated genes
during progression of androgen-independent growth in human prostate
cancer cells. Carcinogenesis. 23:967–975. 2002. View Article : Google Scholar
|
|
53
|
Kelly JA, Lucia MS and Lambert JR: p53
controls prostate-derived factor/macrophage inhibitory
cytokine/NSAID-activated gene expression in response to cell
density, DNA damage and hypoxia through diverse mechanisms. Cancer
Lett. 277:38–47. 2009. View Article : Google Scholar
|
|
54
|
Mimeault M and Batra SK: Divergent
molecular mechanisms underlying the pleiotropic functions of
macrophage inhibitory cytokine-1 in cancer. J Cell Physiol.
224:626–635. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Huang CY, Beer TM, Higano CS, et al:
Molecular alterations in prostate carcinomas that associate with
in vivo exposure to chemotherapy: identification of a
cytoprotective mechanism involving growth differentiation factor
15. Clin Cancer Res. 13:5825–5833. 2007.PubMed/NCBI
|
|
56
|
Zhao L, Lee BY, Brown DA, et al:
Identification of candidate biomarkers of therapeutic response to
docetaxel by proteomic profiling. Cancer Res. 69:7696–7703. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Mimeault M, Johansson SL and Batra SK:
Marked improvement of cytotoxic effects induced by docetaxel on
highly metastatic and androgen-independent prostate cancer cells by
downregulating macrophage inhibitory cytokine-1. Br J Cancer.
108:1079–1091. 2013. View Article : Google Scholar
|
|
58
|
Shiota M, Bishop JL, Nip KM, et al: Hsp27
regulates epithelial mesenchymal transition, metastasis, and
circulating tumor cells in prostate cancer. Cancer Res.
73:3109–3119. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhong B, Sallman DA, Gilvary DL, et al:
Induction of clusterin by AKT - role in cytoprotection against
docetaxel in prostate tumor cells. Mol Cancer Ther. 9:1831–1841.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhang H, Kim JK, Edwards CA, Xu Z,
Taichman R and Wang CY: Clusterin inhibits apoptosis by interacting
with activated Bax. Nat Cell Biol. 7:909–915. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Pucci S, Bonanno E, Pichiorri F, Angeloni
C and Spagnoli LG: Modulation of different clusterin isoforms in
human colon tumorigenesis. Oncogene. 23:2298–2304. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Shannan B, Seifert M, Leskov K, et al:
Challenge and promise: roles for clusterin in pathogenesis,
progression and therapy of cancer. Cell Death Differ. 13:12–19.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sowery RD, Hadaschik BA, So AI, et al:
Clusterin knockdown using the antisense oligonucleotide OGX-011
re-sensitizes docetaxel-refractory prostate cancer PC3 cells to
chemotherapy. BJU Int. 102:389–397. 2008. View Article : Google Scholar
|
|
64
|
Springate CM, Jackson JK, Gleave ME and
Burt HM: Efficacy of an intratumoral controlled release formulation
of clusterin antisense oligonucleotide complexed with chitosan
containing paclitaxel or docetaxel in prostate cancer xenograft
models. Cancer Chemother Pharmacol. 56:239–247. 2005. View Article : Google Scholar
|
|
65
|
Shiota M, Zardan A, Takeuchi A, et al:
Clusterin mediates TGF-β-induced epithelial-mesenchymal transition
and metastasis via Twist1 in prostate cancer cells. Cancer Res.
72:5261–5272. 2012.PubMed/NCBI
|
|
66
|
Wu K, Xie D, Zou Y, et al: The mechanism
of DAB2IP in chemoresistance of prostate cancer cells. Clin Cancer
Res. 19:4740–4749. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Heldin CH, Rubin K, Pietras K and Ostman
A: High interstitial fluid pressure - an obstacle in cancer
therapy. Nat Rev Cancer. 4:806–813. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Netti PA, Hamberg LM, Babich JW, et al:
Enhancement of fluid filtration across tumor vessels: implication
for delivery of macromolecules. Proc Natl Acad Sci USA.
96:3137–3142. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Tomic TT, Gustavsson H, Wang W, Jennbacken
K, Welen K and Damber JE: Castration resistant prostate cancer is
associated with increased blood vessel stabilization and elevated
levels of VEGF and Ang-2. Prostate. 72:705–712. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Gustavsson H, Welen K and Damber JE:
Transition of an androgen-dependent human prostate cancer cell line
into an androgen-independent subline is associated with increased
angiogenesis. Prostate. 62:364–373. 2005. View Article : Google Scholar
|
|
71
|
Gustavsson H, Wang W, Jennbacken K, Welen
K and Damber JE: ADAMTS1, a putative anti-angiogenic factor, is
decreased in human prostate cancer. BJU Int. 104:1786–1790. 2009.
View Article : Google Scholar
|
|
72
|
Eberhard A, Kahlert S, Goede V, Hemmerlein
B, Plate KH and Augustin HG: Heterogeneity of angiogenesis and
blood vessel maturation in human tumors: implications for
antiangiogenic tumor therapies. Cancer Res. 60:1388–1393. 2000.
|
|
73
|
Netti PA, Baxter LT, Boucher Y, Skalak R
and Jain RK: Time-dependent behavior of interstitial fluid pressure
in solid tumors: implications for drug delivery. Cancer Res.
55:5451–5458. 1995.PubMed/NCBI
|
|
74
|
Wilson C, Scullin P, Worthington J, et al:
Dexamethasone potentiates the antiangiogenic activity of docetaxel
in castration-resistant prostate cancer. Br J Cancer. 99:2054–2064.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Sweeney CJ, Miller KD, Sissons SE, et al:
The antiangiogenic property of docetaxel is synergistic with a
recombinant humanized monoclonal antibody against vascular
endothelial growth factor or 2-methoxyestradiol but antagonized by
endothelial growth factors. Cancer Res. 61:3369–3372. 2001.
|
|
76
|
Hotchkiss KA, Ashton AW, Mahmood R,
Russell RG, Sparano JA and Schwartz EL: Inhibition of endothelial
cell function in vitro and angiogenesis in vivo by
docetaxel (taxotere): association with impaired repositioning of
the microtubule organizing center. Mol Cancer Ther. 1:1191–1200.
2002.PubMed/NCBI
|
|
77
|
Murtagh J, Lu H and Schwartz EL:
Taxotere-induced inhibition of human endothelial cell migration is
a result of heat shock protein 90 degradation. Cancer Res.
66:8192–8199. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Erten C, Karaca B, Kucukzeybek Y, et al:
Regulation of growth factors in hormone- and drug-resistant
prostate cancer cells by synergistic combination of docetaxel and
octreotide. BJU Int. 104:107–114. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Bok RA, Halabi S, Fei DT, et al: Vascular
endothelial growth factor and basic fibroblast growth factor urine
levels as predictors of outcome in hormone-refractory prostate
cancer patients: a cancer and leukemia group B study. Cancer Res.
61:2533–2536. 2001.
|
|
80
|
Tatum JL, Kelloff GJ, Gillies RJ, et al:
Hypoxia: importance in tumor biology, noninvasive measurement by
imaging, and value of its measurement in the management of cancer
therapy. Int J Radiat Biol. 82:699–757. 2006. View Article : Google Scholar
|
|
81
|
Forde JC, Perry AS, Brennan K, et al:
Docetaxel maintains its cytotoxic activity under hypoxic conditions
in prostate cancer cells. Urol Oncol. 30:912–919. 2012. View Article : Google Scholar
|
|
82
|
Thews O, Gassner B, Kelleher DK, Schwerdt
G and Gekle M: Impact of hypoxic and acidic extracellular
conditions on cytotoxicity of chemotherapeutic drugs. Adv Exp Med
Biol. 599:155–161. 2007. View Article : Google Scholar
|
|
83
|
Domanska UM, Timmer-Bosscha H, Nagengast
WB, et al: CXCR4 inhibition with AMD3100 sensitizes prostate cancer
to docetaxel chemotherapy. Neoplasia. 14:709–718. 2012.PubMed/NCBI
|
|
84
|
Sun YX, Wang J, Shelburne CE, et al:
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers
(PCa) in vivo. J Cell Biochem. 89:462–473. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Engl T, Relja B, Marian D, et al: CXCR4
chemokine receptor mediates prostate tumor cell adhesion through
α5 and β3 integrins. Neoplasia. 8:290–301.
2006.
|
|
86
|
Akashi T, Koizumi K, Tsuneyama K, Saiki I,
Takano Y and Fuse H: Chemokine receptor CXCR4 expression and
prognosis in patients with metastatic prostate cancer. Cancer Sci.
99:539–542. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Taichman RS, Cooper C, Keller ET, Pienta
KJ, Taichman NS and McCauley LK: Use of the stromal cell-derived
factor-1/CXCR4 pathway in prostate cancer metastasis to bone.
Cancer Res. 62:1832–1837. 2002.PubMed/NCBI
|
|
88
|
Shiozawa Y, Pedersen EA, Havens AM, et al:
Human prostate cancer metastases target the hematopoietic stem cell
niche to establish footholds in mouse bone marrow. J Clin Invest.
121:1298–1312. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Desarnaud F, Geck P, Parkin C, Carpinito G
and Makarovskiy AN: Gene expression profiling of the androgen
independent prostate cancer cells demonstrates complex mechanisms
mediating resistance to docetaxel. Cancer Biol Ther. 11:204–212.
2011. View Article : Google Scholar
|
|
90
|
Bjartell A, Montironi R, Berney DM and
Egevad L: Tumour markers in prostate cancer II: diagnostic and
prognostic cellular biomarkers. Acta Oncol. 50(Suppl 1): 76–84.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Stamey TA, Yang N, Hay AR, McNeal JE,
Freiha FS and Redwine E: Prostate-specific antigen as a serum
marker for adenocarcinoma of the prostate. N Engl J Med.
317:909–916. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Catalona WJ, Smith DS, Ratliff TL, et al:
Measurement of prostate-specific antigen in serum as a screening
test for prostate cancer. N Engl J Med. 324:1156–1161. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Smith DC, Dunn RL, Strawderman MS and
Pienta KJ: Change in serum prostate-specific antigen as a marker of
response to cytotoxic therapy for hormone-refractory prostate
cancer. J Clin Oncol. 16:1835–1843. 1998.PubMed/NCBI
|
|
94
|
Petrylak DP, Ankerst DP, Jiang CS, et al:
Evaluation of prostate-specific antigen declines for surrogacy in
patients treated on SWOG 99–16. J Natl Cancer Inst. 98:516–521.
2006.PubMed/NCBI
|
|
95
|
Colloca G: Prostate-specific antigen
kinetics as a surrogate endpoint in clinical trials of metastatic
castration-resistant prostate cancer: a review. Cancer Treat Rev.
38:1020–1026. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Berry W and Eisenberger M: Achieving
treatment goals for hormone-refractory prostate cancer with
chemotherapy. Oncologist. 10(Suppl 3): 30–39. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Ross RW, Galsky MD, Febbo P, et al: Phase
2 study of neoadjuvant docetaxel plus bevacizumab in patients with
high-risk localized prostate cancer: a Prostate Cancer Clinical
Trials Consortium trial. Cancer. 118:4777–4784. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Sokoll LJ, Sanda MG, Feng Z, et al: A
prospective, multicenter, National Cancer Institute Early Detection
Research Network study of [-2]proPSA: improving prostate cancer
detection and correlating with cancer aggressiveness. Cancer
Epidemiol Biomarkers Prev. 19:1193–1200. 2010.
|
|
99
|
Yap TA, Swanton C and de Bono JS:
Personalization of prostate cancer prevention and therapy: are
clinically qualified biomarkers in the horizon? EPMA J. 3:32012.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Sala A, Bettuzzi S, Pucci S, Chayka O,
Dews M and Thomas-Tikhonenko A: Regulation of CLU gene expression
by oncogenes and epigenetic factors implications for tumorigenesis.
Adv Cancer Res. 105:115–132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Girard FP, Byrne J, Downes M, et al:
Detecting soluble clusterin in in-vitro and in-vivo models of
prostate cancer. Neoplasma. 57:488–493. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Miyake H, Muramaki M, Furukawa J,
Kurahashi T and Fujisawa M: Serum level of clusterin and its
density in men with prostate cancer as novel biomarkers reflecting
disease extension. Urology. 75:454–459. 2010. View Article : Google Scholar
|
|
103
|
Sensibar JA, Sutkowski DM, Raffo A, et al:
Prevention of cell death induced by tumor necrosis factor α in
LNCaP cells by overexpression of sulfated glycoprotein-2
(clusterin). Cancer Res. 55:2431–2437. 1995.
|
|
104
|
Sallman DA, Chen X, Zhong B, et al:
Clusterin mediates TRAIL resistance in prostate tumor cells. Mol
Cancer Ther. 6:2938–2947. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
So A, Sinnemann S, Huntsman D, Fazli L and
Gleave M: Knockdown of the cytoprotective chaperone, clusterin,
chemosensitizes human breast cancer cells both in vitro and
in vivo. Mol Cancer Ther. 4:1837–1849. 2005. View Article : Google Scholar
|
|
106
|
Park DC, Yeo SG, Wilson MR, et al:
Clusterin interacts with paclitaxel and confer paclitaxel
resistance in ovarian cancer. Neoplasia. 10:964–972.
2008.PubMed/NCBI
|
|
107
|
Tang Y, Liu F, Zheng C, Sun S and Jiang Y:
Knockdown of clusterin sensitizes pancreatic cancer cells to
gemcitabine chemotherapy by ERK1/2 inactivation. J Exp Clin Cancer
Res. 31:732012. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Breit SN, Johnen H, Cook AD, et al: The
TGF-β superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine
with roles in inflammation, cancer and metabolism. Growth Factors.
29:187–195. 2011.
|
|
109
|
Brown DA, Stephan C, Ward RL, et al:
Measurement of serum levels of macrophage inhibitory cytokine 1
combined with prostate-specific antigen improves prostate cancer
diagnosis. Clin Cancer Res. 12:89–96. 2006. View Article : Google Scholar
|
|
110
|
Selander KS, Brown DA, Sequeiros GB, et
al: Serum macrophage inhibitory cytokine-1 concentrations correlate
with the presence of prostate cancer bone metastases. Cancer
Epidemiol Biomarkers Prev. 16:532–537. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Brown DA, Hance KW, Rogers CJ, et al:
Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15): a potential
screening tool for the prevention of colon cancer? Cancer Epidemiol
Biomarkers Prev. 21:337–346. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Ignatoski KM, Friedman J, Escara-Wilke J,
et al: Change in markers of bone metabolism with chemotherapy for
advanced prostate cancer: interleukin-6 response is a potential
early indicator of response to therapy. J Interferon Cytokine Res.
29:105–112. 2009. View Article : Google Scholar
|
|
113
|
Codony-Servat J, Marin-Aguilera M, Visa L,
et al: Nuclear factor-kappa B and interleukin-6 related docetaxel
resistance in castration-resistant prostate cancer. Prostate.
73:512–521. 2013. View Article : Google Scholar
|
|
114
|
Ito M, Saito K, Yasuda Y, et al:
Prognostic impact of C-reactive protein for determining overall
survival of patients with castration-resistant prostate cancer
treated with docetaxel. Urology. 78:1131–1135. 2011. View Article : Google Scholar
|
|
115
|
Kantoff PW, Higano CS, Shore ND, et al:
Sipuleucel-T immunotherapy for castration-resistant prostate
cancer. N Engl J Med. 363:411–422. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
de Bono JS, Oudard S, Ozguroglu M, et al:
Prednisone plus cabazitaxel or mitoxantrone for metastatic
castration-resistant prostate cancer progressing after docetaxel
treatment: a randomised open-label trial. Lancet. 376:1147–1154.
2010.
|
|
117
|
Yin L, Hu Q and Hartmann RW: Recent
progress in pharmaceutical therapies for castration-resistant
prostate cancer. Int J Mol Sci. 14:13958–13978. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Saad F, Hotte S, North S, et al:
Randomized phase II trial of custirsen (OGX-011) in combination
with docetaxel or mitoxantrone as second-line therapy in patients
with metastatic castrate-resistant prostate cancer progressing
after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res.
17:5765–5773. 2011. View Article : Google Scholar
|
|
119
|
Hudes G, Tagawa ST, Whang YE, et al: A
phase 1 study of a chimeric monoclonal antibody against
interleukin-6, siltuximab, combined with docetaxel in patients with
metastatic castration-resistant prostate cancer. Invest New Drugs.
31:669–676. 2013. View Article : Google Scholar
|
|
120
|
Di Lorenzo G, Figg WD, Fossa SD, et al:
Combination of bevacizumab and docetaxel in docetaxel-pretreated
hormone-refractory prostate cancer: a phase 2 study. Eur Urol.
54:1089–1094. 2008.
|
|
121
|
Kelly WK, Halabi S, Carducci M, et al:
Randomized, double-blind, placebo-controlled phase III trial
comparing docetaxel and prednisone with or without bevacizumab in
men with metastatic castration-resistant prostate cancer: CALGB
90401. J Clin Oncol. 30:1534–1540. 2012. View Article : Google Scholar
|
|
122
|
Adamo V, Noto L, Franchina T, et al:
Emerging targeted therapies for castration-resistant prostate
cancer. Front Endocrinol (Lausanne). 3:732012.PubMed/NCBI
|
|
123
|
Galsky MD and Vogelzang NJ:
Docetaxel-based combination therapy for castration-resistant
prostate cancer. Ann Oncol. 21:2135–2144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Beer TM, Ryan CW, Venner PM, et al:
Intermittent chemotherapy in patients with metastatic
androgen-independent prostate cancer: results from ASCENT, a
double-blinded, randomized comparison of high-dose calcitriol plus
docetaxel with placebo plus docetaxel. Cancer. 112:326–330. 2008.
View Article : Google Scholar
|
